Presentation of Ascelia Pharma at ABGSC Life Science Summit Day and Redeye Orphan Drug Day

2020-06-09
Presentation
Webcast

CEO Magnus Corfitzen presented the company at ABGSC Life Science Summit Day and Redeye Orphan Drug Day. Link to the video presentations our found below.

ABGSC: https://youtu.be/KNRDLYkbooE

Redeye: https://www.redeye.se/video/event-presentation/786947/ascelia-pharma-ceo-magnus-corfitzen-presents-at-orphan-drugs-may-27

About Ascelia Pharma
Ascelia Pharma is an oncology-dedicated orphan drug development company located in Malmö, Sweden. The company’s strategy is to develop drugs, which target unmet medical needs, have an established mode of action and a relatively low development risk. Ascelia Pharma has two drug candidates – Mangoral and Oncoral – currently under development.Mangoral is a novel contrast agent for MR-scans, currently in the pivotal Phase 3 clinical study SPARKLE. Mangoral is developed to improve the visualisation of focal liver lesions (liver metastases or primary tumours) in patient with impaired kidneys that cannot tolerate current gadolinium contrast agents on the market. Oncoral is an oral chemotherapy tablet ready for Phase 2 for the treatment of gastric cancer. Ascelia Pharma is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit http://www.ascelia.com

2020-09-18

First commercial scale manufacturing of Mangoral

Ascelia Pharma AB (publ) (ticker: ACE) (“Ascelia”) today announced that the company has reached a key achievement with the first commercial scale manufacturing of its lead compound Mangoral, currently in pivotal Phase 3 development. The commercial scale manufacturing is an important step towards market launch.
2020-08-20

Quarterly Report Q2-2020: First participant in the hepatic study

Ascelia Pharma AB (publ) (ticker: ACE) today published its quarterly financial report for Q2-2020 (April – June 2020), which is now available on the company’s website: https://www.ascelia.com/tag/reports-presentations/
2020-07-31

Change in number of shares and votes in Ascelia Pharma AB